Why prescribe
EpiPen®?

  • Available as a twin pack: - encourages patients to carry two - both EpiPen® will have same expiry date and lot number
  • Established for over 20 years.
  • Indicated for patients with an acknowledged risk.1
  • Simple and familiar jab administration.
  • EpiPen® is quick to administer in an emergency with a 3 second hold time during injection.
  • Weight classification in line with EAACI guidelines.2
  • EpiPen® has a 24 month shelf life from manufacture and EpiPen Jr® 19 months from manufacture.
  • EpiPen® materials are available to support healthcare professionals and patients

References

  • EpiPen® Summary of Product Characteristics, August 2019.
  • Muraro A. et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy 2014; 69: 1026-45.

EpiPen® and EpiPen® Jr. (adrenaline) Prescribing Information

Presentation:

EpiPen® delivers a single dose of 0.3mg of adrenaline BP 1:1000 (0.3ml) in a sterile solution. EpiPen® Jr. delivers a single dose of 0.15mg adrenaline BP 1:2000 (0.3ml) in a sterile solution. 1.7ml of adrenaline remains in the auto-injector after activation.

Indications:

EpiPen® auto injectors are automatic injection devices containing adrenaline for allergic emergencies. The auto injectors should be used only by a person with a history or an acknowledged risk of an anaphylactic reaction. The autoinjectors are indicated in the emergency treatment of allergic anaphylactic reactions. Anaphylaxis may be caused by insect stings or bites, foods, drugs and other allergens as well as idiopathic or exercise-induced anaphylaxis.

Dosage and administration:

ADULTS: Administration of 0.3mg adrenaline (EpiPen®) intramuscularly.

CHILDREN: The appropriate dosage may be 0.15mg (EpiPen® Jr.) for children 7.5-25kg body weight and 0.3mg (EpiPen®) adrenaline for children >25kg body weight, or at the discretion of the physician. EpiPen® should only be injected into the anterolateral aspect of the thigh through clothing if necessary. An initial dose should be administered as soon as symptoms of anaphylaxis are recognised. A second injection with an additional EpiPen® may be administered 5-15 minutes after the first injection, if indicated. It is recommended that patients are prescribed two EpiPen® auto-injectors which they should carry at all times. As EpiPen® is designed for emergency treatment, the patient should always seek immediate medical attention even if symptoms have disappeared.

The effects of adrenaline may be potentiated by tricyclic antidepressants and monoamine oxidase inhibitors. Adrenaline should be used in pregnancy only if the potential benefit justifies any potential risk to the foetus. The patient/carer should be informed about the possibility of biphasic anaphylaxis which is characterised by initial resolution followed by recurrence of symptoms some hours later. Asthmatic patients may be at increased risk of severe anaphylactic reaction. Patients should be warned regarding related allergens and investigated so that their specific allergens can be characterised.

Undesirable effects:

Frequency not known: May include injection site infection, palpitations, tachycardia, hypertension, undesirable effects on the central nervous system, sweating, nausea and vomiting, respiratory difficulty, pallor, dizziness, weakness, tremor, headache, apprehension, nervousness, anxiety and undesirable effects on the CNS. Cardiac arrhythmias may follow administration of adrenaline. Overdoses of adrenaline may cause cerebral haemorrhage or arrhythmias.

Rare: Stress cardiomyopathy.

Contra-indications:

There are no absolute contra-indications to the use of adrenaline in a life-threatening situation.

Precautions:

Avoid the risk of inadvertent intravascular injection.

DO NOT INJECT INTO THE BUTTOCKS. Accidental injection into the hands or feet may result in loss of blood flow to the affected areas. If there is an accidental injection into these areas, advise the patient to go immediately to the nearest A & E or hospital casualty department for treatment. All patients who are prescribed EpiPen® should be thoroughly instructed to understand the indications for use and the correct method of administration. It is strongly advised to educate the patient's parents, caregivers, teachers, for the correct usage, in case support is needed in the emergency situation. In case of injection performed by a caregiver, patient's leg should be kept still to reduce risk of injection site injury. The needle should never be reinserted after use.

In patients with a thick sub-cutaneous fat layer, there is a risk for adrenaline not reaching the muscle tissue resulting in a suboptimal effect. A second injection with an additional EpiPen® may be needed. Use with extreme caution in patients with heart disease and those taking digitalis, mercurial diuretic or quinidine. Adrenaline should only be prescribed to these patients and the elderly if the potential benefit justifies the potential risk. There is a risk of adverse reactions following adrenaline administration in patients with high intraocular pressure, severe renal impairment, prostatic adenoma leading to residual urine, hypercalcaemia and hypokalaemia. In patients with Parkinson's disease, adrenaline may be associated with a transient worsening of Parkinson's symptoms such as rigidity and tremor.

For a complete list of warnings and adverse reactions, you should consult the Summary of Product Characteristics.

Package quantity and basic NHS price:

EpiPen® and EpiPen® Jr. are available as single unit doses at £34.30 each or as a twin pack of 2 Auto-Injectors at £68.60.

Product licence numbers:

EpiPen® Auto-Injector PL 46302/0171.

EpiPen® Jr. Auto-Injector PL 46302/0172.

Legal category:

POM.

Marketing Authorisation Holder:

Mylan Products Ltd., Station Close, Potters Bar, EN6 1 TL, UK.

Date of preparation of prescribing information:

April 2020.

EPI-2020-0208.

Adverse events should be reported. Reporting forms and information can be
found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.  Adverse events should also be reported to Mylan by phone: 0800 121 8267 or by email: ukpharmacovigilance@mylan.com


Are you a UK healthcare professional?

YES
NO

hcp popup title

Mylan Connects is an online platform for UK healthcare professionals.

Across the website you will find news, blogs and product information.

epipen training device

FREE EpiPen® training devices available by registering to Mylan Connects

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.

REGISTER NOW